GlassScriptPhysician profile
Erica A Dee
NPI 1881653905
$4,150.29
in general payments reported to CMS, 2019-2025
29 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $112 · 2023: $619 · 2024: $1,544 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,788.88 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $780.65 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $591.30 | 2021-2025 | Dupixent |
| Csl Behring | $491.71 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $458.49 | 2021-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $399.65 | 2021-2025 | Cuvitru, Takhzyro |
| Pfizer INC. | $130.81 | 2021-2024 | |
| Grifols USA, LLC | $129.20 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Gc Biopharma USA, INC. | $113.58 | 2024-2025 | Alyglo, Alyglo |
| Pharming Healthcare, INC. | $113.13 | 2024-2025 | Ruconest |
| Blueprint Medicines Corporation | $100.84 | 2024-2025 | Ayvakit |
| Kaleo, INC. | $94.34 | 2021-2024 | Auvi-Q |
| Genzyme Corporation | $83.35 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $78.07 | 2025 | |
| Amgen INC. | $72.44 | 2024-2025 | Actimmune |
| Lilly USA, LLC | $66.34 | 2025 | Ebglyss |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedrion Biopharma, INC. | $65.08 | 2024-2025 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Abbvie INC. | $64.91 | 2022-2023 | |
| Ars Pharmaceuticals Operations, INC. | $52.60 | 2025 | Neffy |
| Octapharma USA, INC. | $46.30 | 2025 | Cutaquig |
| Cycle Pharmaceuticals INC | $29.88 | 2024-2025 | Sajazir |
| Invivyd INC | $26.32 | 2025 | Pemgarda |
| Teva Pharmaceuticals USA, INC. | $24.40 | 2021 | |
| Verona Pharma, INC. | $22.87 | 2025 | Ohtuvayre |
| Incyte Corporation | $22.47 | 2023 | Opzelura |
| Galderma Laboratories, L.P. | $20.94 | 2025 | Nemluvio |
| Leo Pharma INC. | $20.87 | 2023 | Adbry |
| Arcutis Biotherapeutics, INC. | $18.76 | 2025 | Zoryve |
| Inspire Medical Systems, INC. | $15.85 | 2024 | Inspire |
| Phadia US INC. | $15.14 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Dee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.